The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists

被引:14
作者
Coppolino, Giuseppe [1 ]
Simeoni, Mariadelina [1 ]
Summaria, Chiara [1 ]
Postorino, Maria Concetta [2 ]
Rivoli, Laura [1 ]
Strazzulla, Alessio [2 ]
Torti, Carlo [2 ]
Fuiano, Giorgio [1 ]
机构
[1] Univ Hosp Magna Graecia, Dept Med & Surg Sci, Unit Nephrol & Dialysis, I-88100 Catanzaro, Italy
[2] Univ Hosp Magna Graecia, Dept Med & Surg Sci, Infect Dis Unit, I-88100 Catanzaro, Italy
关键词
Tenofovir; Tenofovir disoproxil; Renal disease; Chronic kidney disease; Renal failure; Haemodialysis; Peritoneal dialysis; Renal transplant; HIV-INFECTED PATIENTS; GELATINASE-ASSOCIATED LIPOCALIN; CHRONIC KIDNEY-DISEASE; LONG-TERM EFFICACY; DISOPROXIL FUMARATE; ANTIVIRAL ACTIVITY; ANTIRETROVIRAL ACTIVITY; TUBULAR DYSFUNCTION; RESCUE THERAPY; ALAFENAMIDE;
D O I
10.1007/s40620-015-0214-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Tenofovir is a nucleotide acting both as an inhibitor of human immunodeficiency (HIV) reverse transcriptase and as a competitor for hepatitis B virus (HBV) RNA-directed DNA polymerase. Approved worldwide in 2001, tenofovir is used as a component of highly active antiretroviral therapy (HAART) in patients with HIV infection. Since 2008, it has also been indicated for treatment of chronic HBV infection or HIV/HBV co-infection. The aim of the treatment consists in suppressing viral replication, thus reducing hepatic complications and improving patient survival. Furthermore, tenofovir could represent an effective therapeutic option in lamivudine-resistant HBV patients. Tenofovir is eliminated unchanged through urine via glomerular filtration (80 %) and proximal tubular secretion (20 %). Thus, alterations in renal clearance may interfere with tenofovir pharmacokinetics and systemic drug concentrations, modifying the therapeutic response. Hence, a renal overload of tenofovir in patients with a pre-existing kidney impairment could result in a worsening of renal function. Following a brief introduction on HBV infection and its therapeutic options, we review the latest evidence, to our knowledge, on renal toxicity of tenofovir in HBV patients and on drug management.
引用
收藏
页码:393 / 402
页数:10
相关论文
共 77 条
[1]   Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection [J].
Agarwal, Kosh ;
Fung, Scott K. ;
Nguyen, Tuan T. ;
Cheng, Wendy ;
Sicard, Eric ;
Ryder, Stephen D. ;
Flaherty, John F. ;
Lawson, Eileen ;
Zhao, Sally ;
Subramanian, G. Mani ;
McHutchison, John G. ;
Gane, Edward J. ;
Foster, Graham R. .
JOURNAL OF HEPATOLOGY, 2015, 62 (03) :533-540
[2]   Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine plus nevirapine regimen [J].
Allavena, C. ;
Bach-Ngohou, K. ;
Billaud, E. ;
Secher, S. ;
Dejoie, T. ;
Reliquet, V. ;
Fakhouri, F. ;
Raffi, F. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (12) :2866-2870
[3]   THE CHANGING EPIDEMIOLOGY OF HEPATITIS-B IN THE UNITED-STATES - NEED FOR ALTERNATIVE VACCINATION STRATEGIES [J].
ALTER, MJ ;
HADLER, SC ;
MARGOLIS, HS ;
ALEXANDER, WJ ;
HU, PY ;
JUDSON, FN ;
MARES, A ;
MILLER, JK ;
MOYER, LA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (09) :1218-1222
[4]   How to manage HIV-infected patients with chronic kidney disease in the HAART era [J].
Ando, Minoru ;
Tsuchiya, Ken ;
Nitta, Kosaku .
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2012, 16 (03) :363-372
[5]  
[Anonymous], 2009, Hepatitis B vaccines: WHO position paper, V84, P405
[6]  
[Anonymous], 2013, HEPATOLOGY, V58, p626A, DOI [10.1002/hep.26855, DOI 10.1002/HEP.26855]
[7]  
[Anonymous], 2013, Global policy report on the prevention and control of viral hepatitis in WHO member states
[8]   Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity [J].
Bam, Rujuta A. ;
Yant, Stephen R. ;
Cihlar, Tomas .
ANTIVIRAL THERAPY, 2014, 19 (07) :687-692
[9]   Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors [J].
Bam, Rujuta A. ;
Birkus, Gabriel ;
Babusis, Darius ;
Cihlar, Tomas ;
Yant, Stephen R. .
ANTIVIRAL THERAPY, 2014, 19 (07) :669-677
[10]   Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients [J].
Berg, Thomas ;
Zoulim, Fabien ;
Moeller, Bernd ;
Trinh, Huy ;
Marcellin, Patrick ;
Chan, Sing ;
Kitrinos, Kathryn M. ;
Dinh, Phillip ;
Flaherty, John F., Jr. ;
McHutchison, John G. ;
Manns, Michael .
JOURNAL OF HEPATOLOGY, 2014, 60 (04) :715-722